DJ1 and α-Synuclein as CSF biomarkers and gene polymorphisms: association with clinical parameters in Parkinson’s disease
Objective: To analyze the CSF α-Synuclein and DJ1 Biomarkers correlating with SNCA and DJ1 gene polymorphisms and clinical parameters in PD. Background: Currently there is…Genetic Profiling of Early Synucleinopathy in Rat Nigrostriatal Dopamine Neurons
Objective: Identification of changes in gene expression in rat nigral neurons associated with early phases of synucleinopathy. Background: Early phases of synucleinopathies such as Parkinson’s…Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advanced Parkinson’s Disease
Objective: To assess serum pharmacokinetics (PK) and cerebrospinal fluid (CSF) concentrations of nilotinib as well as CSF biomarker changes in NILO-PD study. Background: Several cell…Male-specific exacerbation of susceptibility to α-synuclein pre-formed fibrils by developmental dieldrin exposure in mice
Objective: To determine whether developmental exposure to dieldrin exacerbates susceptibility to α-synuclein (α-syn) preformed fibril (PFF)-induced synucleinopathy in adulthood. Background: Parkinson’s disease (PD) is characterized…Deposition of phosphorylated α-synuclein in the muscularis externa of the gastrointestinal tract in patients with prodromal Parkinson’s disease
Objective: In the present study, we investigated Lewy pathology in the enteric nervous system (ENS) of seven Parkinson’s disease (PD) patients who underwent a gastrectomy,…PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease; Part 1 Week-52 results
Objective: Evaluate efficacy and safety of prasinezumab following 52 weeks of treatment in participants with early Parkinson’s disease (PD). Background: Prasinezumab is a humanized monoclonal…Characterization of Lewy bodies-induced neurodegeneration and synucleopathy in wild-type mice
Objective: To investigate the Lewy-body-induced degeneration and synucleopathy in wild-type mice while focusing upon origin of the Lewy bodies. Background: Neurodegenerative diseases, such as Parkinson’s…A study of gut microbiota dynamics in Parkinsonian mice
Objective: To examine gut microbiota in the M83 mouse model of PD. Background: Parkinson’s disease (PD) is a chronic neurodegenerative disease characterized by motor and…Phase I Study Design of a Leucine-Rich Repeat Kinase 2 (LRRK2) Antisense Oligonucleotide, for Parkinson’s Disease
Objective: We will present the preclinical efficacy and safety data and the design of the first in human trial of an antisense oligonucleotide (ASO) for…Emergence of stealth polymorphs that escape α-synuclein amyloid monitoring, take over and acutely spread in neurons
Objective: To unravel the existence of stealth polymorphs of α-synuclein. Background: The conformational strain diversity characterizing α-synuclein (α-syn) amyloid fibrils is possibly at the origin of the…
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 60
- Next Page »